Case: Federal Trade Commission v. Direct Marketing Concepts, Inc.1
Facts: Direct Marketing Concepts, Inc., broadcast an infomercial for Coral Calcium that featured a
spokesperson named Robert Barefoot. In the ad, his claims were as bare as his feet. He asserted that
virtually all diseases — heart disease, cancer, lupus, multiple sclerosis, Parkinson’s — are caused by a
condition called acidosis. And that calcium derived from Okinawan coral cures these diseases by
rendering the body more alkaline: “I’ve had 1,000 people tell me how they’ve cured their cancer. I’ve
witnessed people get out of wheelchairs with multiple sclerosis just by getting on the coral.”
To bolster his claims, Barefoot noted that unspecified articles from the Journal of the American Medical
Association and the New England Journal of Medicine “said that calcium supplements reverse cancer . . .
that’s a quote.” During an 18 month period, this infomercial generated $54 million in sales.
The FTC filed suit against the company and its owners, alleging that the infomercials were deceptive. The
trial court granted the FTC’s motion for summary judgment, ruling that the infomercials were misleading
as a matter of law and, therefore, there was no need for a trial. The defendants appealed.
Issue: Were these infomercials misleading as a matter of law?
Excerpts from Judge Thompson’s Decision: When the FTC brings an action based on the theory that
advertising is deceptive because the advertisers lacked a reasonable basis for their claims, the FTC must:
(1) demonstrate what evidence would in fact establish such a claim in the relevant scientific community;
and (2) compare the advertisers’ evidence to that required by the scientific community to see if the claims
have been established.
On the first prong, the FTC produced four expert declarations which demonstrated that the claims
could be substantiated by double-blind, placebo-controlled human studies. To be sure, there may be other
scientific evidence that could be sufficient. But the government established that some scientific evidence
is required for substantiation, and thus satisfied the first prong. Because the Defendants neither produced
nor pointed to any evidence to raise even the tiniest of fact issues, summary judgment was appropriate on
the first prong.
On the second prong, the FTC relied on the same four expert declarations, in which the experts compared
the Defendants’ evidence to the available literature and concluded in each case that the Defendants’
evidence was woefully inadequate. The experts specifically opined that: (1) there was no evidence that
calcium cures cancer; (2) there was some evidence that calcium might lower blood pressure but none that
it cures heart disease; (3) there was no evidence whatsoever that calcium has any effect on autoimmune
disorders; [and] (4) there has been no research published in the Journal of the American Medical
Association or the New England Journal of Medicine indicating that calcium “reverses” cancer.
The record contains a slew of documents, including excerpts from Barefoot’s books, excerpts from
Barefoot’s deposition testimony, a number of popular science and pseudoscientific articles, and one
preliminary study. Barefoot’s books present jumbles of quotes from scientists, scientific review articles,
and scientific studies interspersed with references to Reader’s Digest and other general-consumption
reductions of these studies. However, none of these scientists or studies supports the panacean claims
made in the Coral Calcium infomercial. The Defendants therefore engaged in deceptive advertising as a
matter of law.
The Defendants attempt to head off the above analysis by asserting that their infomercials advanced no
actual health claims but, instead, presented only puffery which was further attenuated by the presence of
general disclaimers. However, specific and measurable claims are not puffery, and may be the subject of
deceptive advertising claims. [T]he Defendants’ infomercials presented specific and measurable health
claims.
Disclaimers or qualifications in any particular ad are not adequate to avoid liability unless they are
sufficiently prominent and unambiguous to change the apparent meaning of the claims and to leave an
1 624 F.3d 1; 2010 U.S. App. LEXIS 21743 UNITED STATES COURT OF APPEALS FOR THE FIRST
CIRCUIT, 2010